open access

Vol 13, No 3 (2018)
Original Papers
Published online: 2018-07-15
Get Citation

Assessment of serum adiponectin and leptin levels in patients with ischaemic heart disease: an association with the ejection fraction, coronary calcium score and coronary angiogram

Marwan S. Al-Nimer, Adil H. Alhusseiny, Ahood Kh Ibrahim
DOI: 10.5603/FC.2018.0041
·
Folia Cardiologica 2018;13(3):204-209.

open access

Vol 13, No 3 (2018)
Original Papers
Published online: 2018-07-15

Abstract

Introduction. Adiponectin is an adipose tissue-derived adipocytokine protein, while leptin is the protein that maintains the body weight in humans via its effect on the hypothalamus. These hormones interact at different levels of cardio-metabolic risk factors. This study aimed to assess the serum levels of adiponectin and leptin in patients with ischaemic heart disease and subjected to coronary calcium scoring (CCS) and coronary angiography. Material and methods. We included 59 patients with ischaemic heart disease and 20 healthy subjects served as a control in this study. The patients were assessed by electrocardiograph, echocardiograph, coronary angiogram and coronary computerised tomography (CCT) for the assessment of CCS. Serum levels of adiponectin and leptin were determined by using enzyme-linked immunosorbent assay (ELISA) technique. Results. Coronary computed tomography (CT) investigation explored, that 30.5% of patients had positive calcium score and 67.8% of patients did not show evidence of coronary changes by CT angiograph. The patients had significantly high leptin and low adiponectin levels compared with healthy subjects. Serum leptin levels were significantly low in patients with positive CCS and angiogram, compared with those who had no abnormal CCT. Significant positive correlation between ejection fraction and serum leptin (r = 0.285, p < 0.05) and non-significant correlation with serum adiponectin were observed. Conclusions. Serum leptin and adiponectin levels are useful determinants in patients with ischaemic heart disease, as high serum leptin levels are associated with negative coronary CT and positively correlated with left ventricular ejection fraction.

Abstract

Introduction. Adiponectin is an adipose tissue-derived adipocytokine protein, while leptin is the protein that maintains the body weight in humans via its effect on the hypothalamus. These hormones interact at different levels of cardio-metabolic risk factors. This study aimed to assess the serum levels of adiponectin and leptin in patients with ischaemic heart disease and subjected to coronary calcium scoring (CCS) and coronary angiography. Material and methods. We included 59 patients with ischaemic heart disease and 20 healthy subjects served as a control in this study. The patients were assessed by electrocardiograph, echocardiograph, coronary angiogram and coronary computerised tomography (CCT) for the assessment of CCS. Serum levels of adiponectin and leptin were determined by using enzyme-linked immunosorbent assay (ELISA) technique. Results. Coronary computed tomography (CT) investigation explored, that 30.5% of patients had positive calcium score and 67.8% of patients did not show evidence of coronary changes by CT angiograph. The patients had significantly high leptin and low adiponectin levels compared with healthy subjects. Serum leptin levels were significantly low in patients with positive CCS and angiogram, compared with those who had no abnormal CCT. Significant positive correlation between ejection fraction and serum leptin (r = 0.285, p < 0.05) and non-significant correlation with serum adiponectin were observed. Conclusions. Serum leptin and adiponectin levels are useful determinants in patients with ischaemic heart disease, as high serum leptin levels are associated with negative coronary CT and positively correlated with left ventricular ejection fraction.

Get Citation

Keywords

leptin, adiponectin, coronary calcium score

About this article
Title

Assessment of serum adiponectin and leptin levels in patients with ischaemic heart disease: an association with the ejection fraction, coronary calcium score and coronary angiogram

Journal

Folia Cardiologica

Issue

Vol 13, No 3 (2018)

Pages

204-209

Published online

2018-07-15

DOI

10.5603/FC.2018.0041

Bibliographic record

Folia Cardiologica 2018;13(3):204-209.

Keywords

leptin
adiponectin
coronary calcium score

Authors

Marwan S. Al-Nimer
Adil H. Alhusseiny
Ahood Kh Ibrahim

References (26)
  1. Magkos F, Sidossis LS. Recent advances in the measurement of adiponectin isoform distribution. Curr Opin Clin Nutr Metab Care. 2007; 10(5): 571–575.
  2. Kunita E, Yamamoto H, Kitagawa T, et al. Association between plasma high-molecular-weight adiponectin and coronary plaque characteristics assessed by computed tomography angiography in conditions of visceral adipose accumulation. Circ J. 2012; 76(7): 1687–1696.
  3. Li R, Chen Lz, Zhao Sp, et al. Inflammation activation contributes to adipokine imbalance in patients with acute coronary syndrome. PLoS One. 2016; 11(3): e0151916.
  4. Alkofide H, Huggins GS, Ruthazer R, et al. Serum adiponectin levels in patients with acute coronary syndromes: serial changes and relation to infarct size. Diab Vasc Dis Res. 2015; 12(6): 411–419.
  5. Chen CY, Asakura M, Asanuma H, et al. Plasma adiponectin levels predict cardiovascular events in the observational Arita Cohort Study in Japan: the importance of the plasma adiponectin levels. Hypertens Res. 2012; 35(8): 843–848.
  6. Komura N, Kihara S, Sonoda M, et al. Osaka CAD Group. Clinical significance of high-molecular weight form of adiponectin in male patients with coronary artery disease. Circ J. 2008; 72(1): 23–28.
  7. Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol. 2011; 17(23): 2801–2811.
  8. Aoqui C, Cuppari L, Kamimura MA, et al. Increased visceral adiposity is associated with coronary artery calcification in male patients with chronic kidney disease. Eur J Clin Nutr. 2013; 67(6): 610–614.
  9. Wang Yu, Lam KSL, Xu JYu, et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem. 2005; 280(18): 18341–18347.
  10. Motobayashi Y, Izawa-Ishizawa Y, Ishizawa K, et al. Adiponectin inhibits insulin-like growth factor-1-induced cell migration by the suppression of extracellular signal-regulated kinase 1/2 activation, but not Akt in vascular smooth muscle cells. Hypertens Res. 2009; 32(3): 188–193.
  11. van Dam AD, Boon MR, Berbée JFP, et al. Targeting white, brown and perivascular adipose tissue in atherosclerosis development. Eur J Pharmacol. 2017; 816: 82–92.
  12. Sundell J, Huupponen R, Raitakari OT, et al. High serum leptin is associated with attenuated coronary vasoreactivity. Obes Res. 2003; 11(6): 776–782.
  13. Csongrádi É, Káplár M, Nagy B, et al. Adipokines as atherothrombotic risk factors in obese subjects: Associations with haemostatic markers and common carotid wall thickness. Nutr Metab Cardiovasc Dis. 2017; 27(6): 571–580.
  14. Puurunen VP, Kiviniemi A, Lepojärvi S, et al. Leptin predicts short-term major adverse cardiac events in patients with coronary artery disease. Ann Med. 2017; 49(5): 448–454.
  15. Wallerstedt SM, Eriksson AL, Niklason A, et al. Serum leptin and myocardial infarction in hypertension. Blood Press. 2004; 13(4): 243–246.
  16. Karakas M, Zierer A, Herder C, et al. Leptin, adiponectin, their ratio and risk of coronary heart disease: results from the MONICA/KORA Augsburg Study 1984-2002. Atherosclerosis. 2010; 209(1): 220–225.
  17. Khafaji HA, Bener AB, Rizk NM, et al. Elevated serum leptin levels in patients with acute myocardial infarction; correlation with coronary angiographic and echocardiographic findings. BMC Res Notes. 2012; 5: 262.
  18. Martin SS, Qasim AN, Rader DJ, et al. C-reactive protein modifies the association of plasma leptin with coronary calcium in asymptomatic overweight individuals. Obesity (Silver Spring). 2012; 20(4): 856–861.
  19. Li X, Zhang Y, Wang M, et al. The prevalence and awareness of cardiometabolic risk factors in Southern Chinese population with coronary artery disease. ScientificWorldJournal. 2013; 2013: 416192.
  20. Oliveira GB, França JÍ, Piegas LS. Serum adiponectin and cardiometabolic risk in patients with acute coronary syndromes. Arq Bras Cardiol. 2013; 101(5): 399–409.
  21. Yamamoto H, Kitagawa T, Kihara Y. Clinical implications of the coronary artery calcium score in Japanese patients. J Atheroscler Thromb. 2014; 21(11): 1101–1108.
  22. de Faria AP, Modolo R, Fontana V, et al. Adipokines: novel players in resistant hypertension. J Clin Hypertens (Greenwich). 2014; 16(10): 754–759.
  23. de Faria AP, Ritter AMV, Sabbatini AR, et al. Effects of leptin and leptin receptor SNPs on clinical- and metabolic-related traits in apparent treatment-resistant hypertension. Blood Press. 2017; 26(2): 74–80.
  24. Al-Hamodi Z, Al-Habori M, Al-Meeri A, et al. Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus. Diabetol Metab Syndr. 2014; 6(1): 99.
  25. Lodh M, Goswami B, Parida A, et al. Assessment of serum leptin, pregnancy-associated plasma protein A and CRP levels as indicators of plaque vulnerability in patients with acute coronary syndrome. Cardiovasc J Afr. 2012; 23(6): 330–335.
  26. Moroi M, Akter S, Nakazato R, et al. Lower ratio of high-molecular-weight adiponectin level to total may be associated with coronary high-risk plaque. BMC Res Notes. 2013; 6: 83.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl